Insmed

INSMED CMO Martina Flammer Sells 869 Shares at $152.44 on Feb 5, 2026.

Insmed to release Q4 FY25 financial results, host conference call on Feb 19

INSMED Executives Sell Shares Amid Recent Market Volatility

Insmed's 15-min chart sees MACD Death Cross, KDJ Death Cross

Insmed's Brensocatib Pipeline Setback Conceals Potential Dupixent-Like Launch in 2025.

Catalyst<ul> <li>Most analysts rate INSM Buy or Strong Buy, showing broad institutional optimism.</li> <li>The company maintains strong cash reserves relative to market value.</li></ul>Risk<ul> <li>Fund flows show net outflow across all order sizes, indicating investor caution or pessimism.</li> <li>Technical indicators show that the market is in a volatile state and the direction is not clear enough.</li> <li>At least one major firm maintains a Neutral rating, citing valuation concerns.</li></ul>

Key Factors

Insmed (INSM) is scheduled to release Q4 FY25 financial results and host a conference call on February 19, 2026. Insmed's Chief Medical Officer Martina Flammer sold 869 shares at $152.44 on February 5, 2026. Insmed executives including CMO Flammer and CFO Bonstein sold shares between February 2 and February 3, 2026.

INSM News